| Ytd | 62.97% | |
| 1y | 49.36% |
| Open | 16.27 | Prev Close | 16.34 | Low | 16.10 | High | 16.48 | Mkt Cap | 571.14M |
| Vol | 402.60K | Avg Vol | 568.13K | EPS | 0.01 | P/E | 1646.00 | Forward P/E | -35.75 |
| Beta | 0.76 | Short Ratio | 5.26 | Inst. Own | 38.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 14.00 | 200-d Avg | 11.07 | 1yr Est | 21.33 |
DCTH News
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors?
If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Sys
The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in De
If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Sys
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors?
The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in De
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) wi
Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri
Delcath Systems NASDAQ: DCTH reported second-quarter 2026 revenue of $29.1 million, up from $24.2 mi
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks
Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst
Delcath Systems (NASDAQ:DCTH) sees FY2026 sales of $104.000 million-$108.000 million vs $103.242 mil
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
On May 22, 2026, Delcath Systems Inc (DCTH) shares fell 3.8%, bringing the current price to $11.02.
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”)
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
Delcath Systems, Inc. (DCTH) Q1 2026 Earnings Call Transcript
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.03 per share versus the Zacks Cons
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.03) per share which beat the analyst
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on liver-directed ca
BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the pri
Delcath Systems (NASDAQ:DCTH) FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.05) per share which beat the analyst
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) w
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional
Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional
Stephens & Co. analyst Sudan Loganathan maintains Delcath Systems (NASDAQ:DCTH) with a Overwe
Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.02 per share which beat the analyst
Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:DCTH) with a Buy and main
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) wi
Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of app
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) wi
Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst